Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?

P. Gazzaniga; C. Raimondi; A. Gradilone; G. Biondi Zoccai; C. Nicolazzo; O. Gandini; F. Longo; S. Tomao; G. Lo Russo; P. Seminara; B. Vincenzi; I. Chimenti; M. Cristofanilli; L. Frati; E. Cortesi

doi:10.1007/s00432-013-1450-0

Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?

P. Gazzaniga, C. Raimondi, A. Gradilone, G. Biondi Zoccai, C. Nicolazzo, O. Gandini, F. Longo, S. Tomao, G. Lo Russo, P. Seminara, B. Vincenzi, I. Chimenti, M. Cristofanilli, L. Frati, E. Cortesi

www.neuromed.it

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level. Materials and methods: We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL). Results: An overall comparison was made between patients with 0, 1-2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014). Conclusions: The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1-2 CTC should be switched from the favorable prognostic group - conventionally defined by the presence of

Original language	English
Pages (from-to)	1411-1416
Number of pages	6
Journal	Journal of Cancer Research and Clinical Oncology
Volume	139
Issue number	8
DOIs	https://doi.org/10.1007/s00432-013-1450-0
Publication status	Published - Aug 2013

Keywords

CellSearch
Circulating tumor cells
Colorectal cancer
Cutoff

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1007/s00432-013-1450-0

Cite this

Gazzaniga, P., Raimondi, C., Gradilone, A., Biondi Zoccai, G., Nicolazzo, C., Gandini, O., Longo, F., Tomao, S., Lo Russo, G., Seminara, P., Vincenzi, B., Chimenti, I., Cristofanilli, M., Frati, L., & Cortesi, E. (2013). Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff? Journal of Cancer Research and Clinical Oncology, 139(8), 1411-1416. https://doi.org/10.1007/s00432-013-1450-0

Gazzaniga, P, Raimondi, C, Gradilone, A, Biondi Zoccai, G, Nicolazzo, C, Gandini, O, Longo, F, Tomao, S, Lo Russo, G, Seminara, P, Vincenzi, B, Chimenti, I, Cristofanilli, M, Frati, L & Cortesi, E 2013, 'Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?', Journal of Cancer Research and Clinical Oncology, vol. 139, no. 8, pp. 1411-1416. https://doi.org/10.1007/s00432-013-1450-0

@article{2243eabcd43a40c3889e0c34a5b17abd,

title = "Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?",

abstract = "Purpose: To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level. Materials and methods: We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL). Results: An overall comparison was made between patients with 0, 1-2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014). Conclusions: The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1-2 CTC should be switched from the favorable prognostic group - conventionally defined by the presence of ",

keywords = "CellSearch, Circulating tumor cells, Colorectal cancer, Cutoff",

author = "P. Gazzaniga and C. Raimondi and A. Gradilone and {Biondi Zoccai}, G. and C. Nicolazzo and O. Gandini and F. Longo and S. Tomao and {Lo Russo}, G. and P. Seminara and B. Vincenzi and I. Chimenti and M. Cristofanilli and L. Frati and E. Cortesi",

year = "2013",

month = aug,

doi = "10.1007/s00432-013-1450-0",

language = "English",

volume = "139",

pages = "1411--1416",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "8",

}

TY - JOUR

T1 - Circulating tumor cells in metastatic colorectal cancer

T2 - Do we need an alternative cutoff?

AU - Gazzaniga, P.

AU - Raimondi, C.

AU - Gradilone, A.

AU - Biondi Zoccai, G.

AU - Nicolazzo, C.

AU - Gandini, O.

AU - Longo, F.

AU - Tomao, S.

AU - Lo Russo, G.

AU - Seminara, P.

AU - Vincenzi, B.

AU - Chimenti, I.

AU - Cristofanilli, M.

AU - Frati, L.

AU - Cortesi, E.

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level. Materials and methods: We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL). Results: An overall comparison was made between patients with 0, 1-2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014). Conclusions: The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1-2 CTC should be switched from the favorable prognostic group - conventionally defined by the presence of

AB - Purpose: To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level. Materials and methods: We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL). Results: An overall comparison was made between patients with 0, 1-2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014). Conclusions: The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1-2 CTC should be switched from the favorable prognostic group - conventionally defined by the presence of

KW - CellSearch

KW - Circulating tumor cells

KW - Colorectal cancer

KW - Cutoff

UR - http://www.scopus.com/inward/record.url?scp=84880919497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880919497&partnerID=8YFLogxK

U2 - 10.1007/s00432-013-1450-0

DO - 10.1007/s00432-013-1450-0

M3 - Article

C2 - 23736274

AN - SCOPUS:84880919497

SN - 0171-5216

VL - 139

SP - 1411

EP - 1416

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 8

ER -

Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this